Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Ph+ ALL: Recent reports/studies (2020–2025). Significant improvement in long-term outcomes!!
Highlights Takeaway: Blinatumomab + TKI regimens show high OS/EFS with low transplant rates. Ponatinib improves MRD-neg CR and long-term outcomes.”
More posts about Blinatumomab on OncoDaily.